Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells | |
Zhang, XY; Yeung, ED; Wang, JY; Panzhinskiy, EE; Tong, C; Li, WG; Li, J; Li, J (reprint author), SUNY Buffalo, Dept Pharmacol & Toxicol, Sch Med & Biomed Sci, Buffalo, NY 14214 USA. | |
刊名 | CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
![]() |
2010-08 | |
卷号 | 37期号:8页码:841-847 |
关键词 | AMP-activated protein kinase isoliquiritigenin prostate cancer cells reactive oxygen species |
ISSN号 | 1440-1681 |
DOI | 10.1111/j.1440-1681.2010.05395.x |
文献子类 | Article |
英文摘要 | P>1. Isoliquiritigenin (ISL) is a simple chalcone-type flavonoid derived from liquorice compounds. It has been reported to have anti-oxidative and antitumour activities. The aim of the present study was to investigate the antitumour effect of ISL on prostate cancer cells and to explore the possible signalling mechanisms involved. 2. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The fluorescent probe 2',7'-dichlorofluorescein diacetate (H2DCF-DA) was used to measure intracellular levels of reactive oxygen species (ROS). Mitochondrial membrane potential (Psi(m)) was measured using the mitochondrial probe 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine iodide (JC-1). 3. Isoliquiritigenin treatment (10-100 mu mol/L for 24 h) markedly inhibited the proliferation of both C4-2 and LNCaP prostate cancer cells in a dose-dependent manner. Intriguingly, ISL treatment (10-100 mu mol/L for 24 h) had no effect on the viability of IEC-6 normal epithelial cells. Treatment of C4-2 and IEC-6 cells with 87.0 mu mol/L ISL significantly decreased ROS levels and the Psi(m) of C4-2 cells, but had no effect on either parameter in IEC-6 cells. Furthermore, AMP-activated protein kinase (AMPK) and extracellular-signal regulated kinase (ERK) levels were three to fourfold higher in IEC-6 cells than in C4-2 cells (P < 0.05). 4. The results of the present study suggest that ISL, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer C4-2 cells, which may be attributed, in part, to defective AMPK and ERK signalling pathways in C4-2 compared with IEC-6 cells. |
学科主题 | Pharmacology & Pharmacy ; Physiology |
出版地 | HOBOKEN |
资助项目 | 国家自然科学基金项目 ; 国家留学基金委项目 ; 甘肃省自然科学基金计划 ; 美国国立卫生研究院项目 |
项目编号 | China Scholarship Council ; Gansu Province Natural Science Foundation of China [0710RJZA037] ; National Institutes of Health IDeA Network for Biomedical Research Excellence (INBRE) [5P20RR016474] ; American Heart Association [SDG0835168N] ; American Federation for Ageing [08007] ; National Center for Research Resources [1UL1RR025014-01] |
语种 | 英语 |
WOS记录号 | WOS:000280457100011 |
资助机构 | NSFC ; CSC ; GSSTD ; NIH |
内容类型 | 期刊论文 |
源URL | [http://ir.lzu.edu.cn/handle/262010/121453] ![]() |
专题 | 基础医学院_期刊论文 |
通讯作者 | Li, J (reprint author), SUNY Buffalo, Dept Pharmacol & Toxicol, Sch Med & Biomed Sci, Buffalo, NY 14214 USA. |
推荐引用方式 GB/T 7714 | Zhang, XY,Yeung, ED,Wang, JY,et al. Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells[J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY,2010,37(8):841-847. |
APA | Zhang, XY.,Yeung, ED.,Wang, JY.,Panzhinskiy, EE.,Tong, C.,...&Li, J .(2010).Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells.CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY,37(8),841-847. |
MLA | Zhang, XY,et al."Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells".CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY 37.8(2010):841-847. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论